Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
about
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapyProgress and problems in understanding and managing primary Epstein-Barr virus infectionsAdoptive cell transfer: a clinical path to effective cancer immunotherapyPhase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosisAdoptive T cell therapy: Addressing challenges in cancer immunotherapyAdoptive T-cell therapy for fungal infections in haematology patientsAdoptive T-Cell ImmunotherapyLymphoma Immunotherapy: Current StatusT lymphocytes targeting native receptorsPosttransplant lymphoproliferative disease after pediatric solid organ transplantationImmune regulation of human herpesviruses and its implications for human transplantationNovel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccineA critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection.The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disordersEpstein-Barr virus associated polymorphic lymphoproliferative disorders occurring in nontransplant settings.The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients.Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients.Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.Virus and cell RNAs expressed during Epstein-Barr virus replicationSystemic Epstein-Barr virus positive T-cell lymphoproliferative disease of childhood with hemophagocytic syndrome.Adoptive T-cell therapy: adverse events and safety switches.Herpesvirus infections in organ transplant recipientsEpstein-Barr virus-associated lymphomas.Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management.Prevention and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants.Prospects for immunotherapy of malignant disease.Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.T cell-based therapies for EBV-associated malignancies.A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics.The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.Clinical implications of T cell receptor repertoire analysis after allogeneic stem cell transplantation.Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated MalignanciesTreatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)Strategies for minimizing immunosuppression in kidney transplantation.Cellular immunotherapy for viral infection after HSC transplantation.Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies.Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's diseaseImproving T cell therapy for cancer.Adoptive T-cell transfer in cancer immunotherapy.
P2860
Q24596055-95AF8DC6-8229-4A12-ACFE-05D33632D564Q24597706-25E28F2E-58BD-46BB-B709-4CC16E16D33DQ24644774-820E52EA-8752-40BC-B251-A2C44A9881BCQ24657081-112D610A-709D-4D8D-A631-E94851565CA3Q24805804-E6F6939B-7A40-4E0F-B691-AD25D1CEC397Q26781064-A5CACE76-65D2-4C73-BAC0-D5019E914F04Q26782845-113F63A0-C5A1-4025-94AC-C365AC9133CBQ26782902-0577B54A-F0A9-4408-96C7-1976FB97FCFFQ26853345-3DB32D4A-FF30-40BF-BB3A-B429CDF76E8CQ26866013-1996686A-57B1-4EA6-A133-FC67F75999ECQ26992146-B2E9829F-6FC7-465A-A59B-0CDF7B2C7B8DQ28749468-1ADF1847-4684-467D-A778-E6B4FA687C81Q33841127-52F3A4B6-7BF5-48D4-86E5-65D9EFFBBA26Q34166602-EE5326E9-FC33-483B-B619-B6FFA678416CQ34220305-C760506A-AD2A-4709-9EBC-5634D6F085A3Q34244446-52341980-4DBC-49BF-89A0-417AD022FDF8Q34271690-FC80EDB8-5FFA-45E3-B1BD-647B1472E385Q34353696-0CD5FD77-15AF-401F-989C-0D4CE3038FF6Q34434702-7628521D-19FC-412C-B40C-C327FCF57D0DQ34501864-F9172B62-62A7-43F8-84C3-F89BD8AD6D6DQ34511623-69719E3C-C857-44B5-872A-0A961B78562AQ34579836-73F29B83-7BED-4FCA-B48A-33B84343DF61Q34651670-FDA47270-DB58-4D9D-9CD2-6DB1207B0ED5Q34861980-DCB6E7CA-59CC-46BC-86AD-DAF072525C83Q35001143-DE8353DF-E367-40D8-9C41-76310B090E19Q35041705-18450A17-03BE-45D9-A9A2-F42869A9CFAFQ35083003-764BC09A-60B3-4835-9100-CCB23D7AF006Q35609768-A7775900-817D-47E8-AC09-C21600A691D1Q35639567-2CAB5A14-3DDB-4C48-BB45-5EA444A25667Q35680531-24EF4EF8-8241-4747-964F-25D2D7C9F4F8Q35686137-748B628D-C464-4A61-9692-16CB9C3D49D1Q35809452-44569A32-16AC-495B-9E81-9D7F17076A27Q35829978-A349BE84-8B3D-4F57-BEA8-5239229B89E5Q35849039-16961358-3F5D-451C-ADC3-DFE16D1DD386Q35990853-0B99B8C9-E944-4D96-BE81-AB31BFFC13BEQ35998792-DCC20A31-63F6-44DE-A707-3A8CB50858D6Q36303951-075BEFCD-0F0D-4A1F-AE39-5F371D987C06Q36399791-0B8BB1F6-52F8-4011-9D92-8136EB3FA7CFQ36407236-551623B9-595D-4DA2-AB95-45971A280230Q36471818-318607AB-1925-4575-927E-CEB03FEA3F6E
P2860
Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Activation and adoptive transf ...... t lymphoproliferative disease.
@ast
Activation and adoptive transf ...... t lymphoproliferative disease.
@en
type
label
Activation and adoptive transf ...... t lymphoproliferative disease.
@ast
Activation and adoptive transf ...... t lymphoproliferative disease.
@en
prefLabel
Activation and adoptive transf ...... t lymphoproliferative disease.
@ast
Activation and adoptive transf ...... t lymphoproliferative disease.
@en
P2093
P2860
P50
P356
P1476
Activation and adoptive transf ...... nt lymphoproliferative disease
@en
P2093
A Galbraith
J Douglass
M Sherritt
R Slaughter
S L Elliott
T Williams
P2860
P304
10391-10396
P356
10.1073/PNAS.96.18.10391
P407
P577
1999-08-01T00:00:00Z